目的：为贵州省中药民族药企业的良性可持续发展提供参考。方法：以贵州省9 市、州的129 家中药民族药企业为调查对

象，按地理位置分层抽样55 家开展实地问卷调查，对企业2009－2013 年在相关政策熟悉程度、生产销售、人员配置、自主创新等方

面的内容进行统计分析，并提出发展对策。结果与结论：所调查的企业中，有45.1％表示对相关政策知晓并熟悉，有51.0％表示知

晓但仅了解，仅有3.9％表示基本不了解；近5 年企业年产值与销售收入逐年上涨；近80％的企业的生产技术人员为初级职称或没

有职称，营销部门人员以大专、中专学历为主（分别占47.5％、25.3％），研发人员以本科、大专学历为主（分别占57.0％、33.7％）；近

5 年自主创新投入占销售收入比例平均为2.4％。该省存在以中、小型企业为主、企业对相关政策认识不足、战略调整缓慢、自主创

新投入强度需加强等问题。应进一步加强相关政策宣传，引导企业兼并重组，密切关注行业发展动态，转变自主创新思路，重视基

本药物独家生产品种的研发等。

OBJECTIVE：To provide reference for benign sustainable development of traditional Chinese and ethnic medicine

enterprises in Guizhou. METHODS：Taking 129 traditional Chinese and ethnic medicine enterprises of 9 city and prefecture in Guizhou

as survey object，questionnaires survey was conducted in 55 enterprises by stratified sampling according to location. The data

statistical analysis was carried out in respects of related policies familiarity，product positioning，independent innovation from

2009 to 2013. Relevant development countermeasures were put forward. RESULTS & CONCLUSIONS：45.1％ of enterprises expressed

to know and be familiar with relevant policies，51.0％ expressed to alert but only understand，and 3.9％ said largely unknown.

At the past five years，the annual output value and sales revenue of enterprises had risen year by year. Almost 80％ production

and technical personnel of enterprises had the junior title or no title；marketing department staff mainly had college and secondary

school degree，accounting for 47.5％ and 25.3％ respectively；research personnel mainly had bachelor and college degree，accounting

for 57.0％ and 33.7％ respectively. At the past five years，independent innovation input took up 2.4％ of sales revenue averagely.

There are problems，such as small and medium enterprises occupying dominate position；enterprises lacking of sufficient

understanding on related policies；strategies being adjusted slowly；independent innovation input intensity needing to increase.

Countermeasures and suggestions are put forward，such as strengthening the relevant policy advocacy，guiding corporate mergers

and acquisitions，closely paying attention to industry development，changing innovation ideas，and attaching importance to research

of exclusive production of essential medicine.